Print page |
Email page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
PETALUMA, Calif., Aug 07, 2008 (BUSINESS WIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it will present at Canaccord Adams 28th Annual Global Growth Conference to be held in Boston from August 12-14 at the Intercontinental Boston Hotel.
Hoji Alimi, Oculus' founder and chief executive officer, is scheduled to speak on Wednesday, August 13, 2008 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time) and will discuss the company's strategic initiatives, commercial activities, product pipeline and market opportunities.
Interested parties can access a live audio webcast and slide presentation at http://ir.oculusis.com/events.cfm. An archived presentation will be available on the web site for 30 days.
The Canaccord Adams Global Growth Conference is one of the oldest and largest programs showcasing both publicly traded and privately held growth companies.
About Oculus
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized outside the United States (Europe, India and Mexico) for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. A recently completed U.S. Phase II clinical trial of Microcyn Technology met the primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers.
In addition to the company's existing and under-development therapeutic products, Oculus also develops, manufactures and markets a number of 510k devices and products for both professional and consumer. Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan. More information can be found at the company's web site, www.oculusis.com.
SOURCE: Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. Dan McFadden, 425-753-2105 Director of Public and Investor Relations dmcfadden@oculusis.com or Lippert/Heilshorn & Associates, Inc. Bruce Voss, 310-691-7100 (investors) bvoss@lhai.com Don Markley, 310-691-7100 (investors) dmarkley@lhai.com Jules Abraham, 212-838-3777 (media) jabraham@lhai.com
Copyright Business Wire 2008
News Provided by COMTEX